Contrasting of IQVIA Holdings Inc. (IQV) and Organovo Holdings Inc. (NASDAQ:ONVO)

IQVIA Holdings Inc. (NYSE:IQV) and Organovo Holdings Inc. (NASDAQ:ONVO) are two firms in the Medical Laboratories & Research that compete against each other. Below is a comparison of their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IQVIA Holdings Inc. 144 1.55 192.50M 1.05 152.32
Organovo Holdings Inc. N/A 0.00 129.78M -0.23 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of IQVIA Holdings Inc. and Organovo Holdings Inc.


Table 2 provides us IQVIA Holdings Inc. and Organovo Holdings Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IQVIA Holdings Inc. 133,578,516.41% 3.7% 1.1%
Organovo Holdings Inc. 34,460,966,542.75% -70% -63.4%

Risk and Volatility

IQVIA Holdings Inc. is 12.00% less volatile than Standard & Poor’s 500 because the stock has a beta of 0.88. Organovo Holdings Inc.’s 86.00% more volatile than Standard & Poor’s 500 volatility due to the stock’s 1.86 beta.


1.1 and 1.1 are the respective Current Ratio and a Quick Ratio of IQVIA Holdings Inc. Its rival Organovo Holdings Inc.’s Current and Quick Ratios are 10.3 and 10.2 respectively. Organovo Holdings Inc. has a better chance of clearing its pay short and long-term debts than IQVIA Holdings Inc.

Insider and Institutional Ownership

The shares of both IQVIA Holdings Inc. and Organovo Holdings Inc. are owned by institutional investors at 92.3% and 38.5% respectively. About 0.5% of IQVIA Holdings Inc.’s share are held by insiders. On the other hand, insiders held about 0.7% of Organovo Holdings Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
IQVIA Holdings Inc. -0.9% -0.95% 17.91% 24.78% 31.63% 37.01%
Organovo Holdings Inc. -7.41% -16.45% -59.08% -59.48% -64.68% -56.82%

For the past year IQVIA Holdings Inc. had bullish trend while Organovo Holdings Inc. had bearish trend.


On 8 of the 11 factors IQVIA Holdings Inc. beats Organovo Holdings Inc.

Quintiles IMS Holdings, Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. This segment also provides OneKey, a reference database of healthcare professionals; real-world insights, and various cloud-based applications and related implementation services; and strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Integrated Engagement Services segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. Quintiles IMS Holdings, Inc. serves pharmaceutical, biotechnology, medical device, and healthcare companies. The company was formerly known as Quintiles Transnational Holdings Inc. and changed its name to Quintiles IMS Holdings, Inc. as a result of its merger with IMS Health Holdings, Inc. in October 2016. The company was founded in 1982 and is headquartered in Durham, North Carolina.

Organovo Holdings, Inc., an early commercial stage company, designs and creates functional and three-dimensional (3D) human tissues for use in medical research and therapeutic applications. The company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners. Its 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company offers two commercial products, which include ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing a suite of standardized and 3D human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology, or disease for use in drug discovery and development, and disease modeling; and 3D human tissues for clinical applications, such as therapeutic liver tissue patch. Organovo Holdings, Inc. was founded in 2007 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.